1019 related articles for article (PubMed ID: 28938091)
1. Targeting Metabolism for Cancer Therapy.
Luengo A; Gui DY; Vander Heiden MG
Cell Chem Biol; 2017 Sep; 24(9):1161-1180. PubMed ID: 28938091
[TBL] [Abstract][Full Text] [Related]
2. Targeting metabolic changes in cancer: novel therapeutic approaches.
Bobrovnikova-Marjon E; Hurov JB
Annu Rev Med; 2014; 65():157-70. PubMed ID: 24422570
[TBL] [Abstract][Full Text] [Related]
3. The heterocyclic compound Tempol inhibits the growth of cancer cells by interfering with glutamine metabolism.
Ye S; Xu P; Huang M; Chen X; Zeng S; Wang Q; Chen J; Li K; Gao W; Liu R; Liu J; Shao Y; Zhang H; Xu Y; Zhang Q; Zhong Z; Wei Z; Wang J; Hao B; Huang W; Liu Q
Cell Death Dis; 2020 May; 11(5):312. PubMed ID: 32366855
[TBL] [Abstract][Full Text] [Related]
4. The metabolic alterations of cancer cells.
Sciacovelli M; Gaude E; Hilvo M; Frezza C
Methods Enzymol; 2014; 542():1-23. PubMed ID: 24862258
[TBL] [Abstract][Full Text] [Related]
5. Non-canonical roles for metabolic enzymes and intermediates in malignant progression and metastasis.
Williams D; Fingleton B
Clin Exp Metastasis; 2019 Jun; 36(3):211-224. PubMed ID: 31073762
[TBL] [Abstract][Full Text] [Related]
6. Arginine Deprivation Inhibits the Warburg Effect and Upregulates Glutamine Anaplerosis and Serine Biosynthesis in ASS1-Deficient Cancers.
Kremer JC; Prudner BC; Lange SES; Bean GR; Schultze MB; Brashears CB; Radyk MD; Redlich N; Tzeng SC; Kami K; Shelton L; Li A; Morgan Z; Bomalaski JS; Tsukamoto T; McConathy J; Michel LS; Held JM; Van Tine BA
Cell Rep; 2017 Jan; 18(4):991-1004. PubMed ID: 28122247
[TBL] [Abstract][Full Text] [Related]
7. Targeting cancer metabolism.
Teicher BA; Linehan WM; Helman LJ
Clin Cancer Res; 2012 Oct; 18(20):5537-45. PubMed ID: 23071355
[TBL] [Abstract][Full Text] [Related]
8. Targeting cancer metabolism: a therapeutic window opens.
Vander Heiden MG
Nat Rev Drug Discov; 2011 Aug; 10(9):671-84. PubMed ID: 21878982
[TBL] [Abstract][Full Text] [Related]
9. Review of metabolic pathways activated in cancer cells as determined through isotopic labeling and network analysis.
Dong W; Keibler MA; Stephanopoulos G
Metab Eng; 2017 Sep; 43(Pt B):113-124. PubMed ID: 28192215
[TBL] [Abstract][Full Text] [Related]
10. Action at a distance: allostery and the development of drugs to target cancer cell metabolism.
DeLaBarre B; Hurov J; Cianchetta G; Murray S; Dang L
Chem Biol; 2014 Sep; 21(9):1143-61. PubMed ID: 25237859
[TBL] [Abstract][Full Text] [Related]
11. Cancer-associated isocitrate dehydrogenase 1 (IDH1) R132H mutation and d-2-hydroxyglutarate stimulate glutamine metabolism under hypoxia.
Reitman ZJ; Duncan CG; Poteet E; Winters A; Yan LJ; Gooden DM; Spasojevic I; Boros LG; Yang SH; Yan H
J Biol Chem; 2014 Aug; 289(34):23318-28. PubMed ID: 24986863
[TBL] [Abstract][Full Text] [Related]
12. Altered glutamine metabolism and therapeutic opportunities for lung cancer.
Mohamed A; Deng X; Khuri FR; Owonikoko TK
Clin Lung Cancer; 2014 Jan; 15(1):7-15. PubMed ID: 24377741
[TBL] [Abstract][Full Text] [Related]
13. Metabolic alterations in cancer cells and therapeutic implications.
Hammoudi N; Ahmed KB; Garcia-Prieto C; Huang P
Chin J Cancer; 2011 Aug; 30(8):508-25. PubMed ID: 21801600
[TBL] [Abstract][Full Text] [Related]
14. Targeting metabolic dependencies in pediatric cancer.
Issaq SH; Heske CM
Curr Opin Pediatr; 2020 Feb; 32(1):26-34. PubMed ID: 31789976
[TBL] [Abstract][Full Text] [Related]
15. Novel therapeutic targets of tumor metabolism.
Kishton RJ; Rathmell JC
Cancer J; 2015; 21(2):62-9. PubMed ID: 25815845
[TBL] [Abstract][Full Text] [Related]
16. Isocitrate dehydrogenase variants in cancer - Cellular consequences and therapeutic opportunities.
Liu S; Cadoux-Hudson T; Schofield CJ
Curr Opin Chem Biol; 2020 Aug; 57():122-134. PubMed ID: 32777735
[TBL] [Abstract][Full Text] [Related]
17. Development of Novel Therapeutics Targeting Isocitrate Dehydrogenase Mutations in Cancer.
Sharma H
Curr Top Med Chem; 2018; 18(6):505-524. PubMed ID: 29773061
[TBL] [Abstract][Full Text] [Related]
18. Gerometabolites: the pseudohypoxic aging side of cancer oncometabolites.
Menendez JA; Alarcón T; Joven J
Cell Cycle; 2014; 13(5):699-709. PubMed ID: 24526120
[TBL] [Abstract][Full Text] [Related]
19. Reductive carboxylation supports redox homeostasis during anchorage-independent growth.
Jiang L; Shestov AA; Swain P; Yang C; Parker SJ; Wang QA; Terada LS; Adams ND; McCabe MT; Pietrak B; Schmidt S; Metallo CM; Dranka BP; Schwartz B; DeBerardinis RJ
Nature; 2016 Apr; 532(7598):255-8. PubMed ID: 27049945
[TBL] [Abstract][Full Text] [Related]
20. Targeting metabolic vulnerabilities of cancer: Small molecule inhibitors in clinic.
Tripathi SC; Fahrmann JF; Vykoukal JV; Dennison JB; Hanash SM
Cancer Rep (Hoboken); 2019 Feb; 2(1):e1131. PubMed ID: 32721114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
